|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: H2AFJ |
Gene summary for H2AFJ |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | H2AFJ | Gene ID | 55766 |
| Gene name | H2A.J histone | |
| Gene Alias | H2AFJ | |
| Cytomap | 12p12.3 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A024RAS2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 55766 | H2AFJ | GSM4909285 | Human | Breast | IDC | 9.67e-13 | -4.33e-01 | 0.21 |
| 55766 | H2AFJ | GSM4909286 | Human | Breast | IDC | 3.25e-13 | -3.57e-01 | 0.1081 |
| 55766 | H2AFJ | GSM4909288 | Human | Breast | IDC | 1.19e-02 | -4.33e-01 | 0.0988 |
| 55766 | H2AFJ | GSM4909293 | Human | Breast | IDC | 1.04e-37 | 6.79e-01 | 0.1581 |
| 55766 | H2AFJ | GSM4909294 | Human | Breast | IDC | 3.84e-05 | 2.19e-01 | 0.2022 |
| 55766 | H2AFJ | GSM4909296 | Human | Breast | IDC | 1.95e-12 | 3.48e-01 | 0.1524 |
| 55766 | H2AFJ | GSM4909297 | Human | Breast | IDC | 1.91e-30 | 3.34e-01 | 0.1517 |
| 55766 | H2AFJ | GSM4909301 | Human | Breast | IDC | 2.14e-87 | 1.08e+00 | 0.1577 |
| 55766 | H2AFJ | GSM4909302 | Human | Breast | IDC | 3.63e-10 | 3.16e-01 | 0.1545 |
| 55766 | H2AFJ | GSM4909304 | Human | Breast | IDC | 1.05e-55 | 8.55e-01 | 0.1636 |
| 55766 | H2AFJ | GSM4909306 | Human | Breast | IDC | 3.29e-18 | 5.82e-01 | 0.1564 |
| 55766 | H2AFJ | GSM4909307 | Human | Breast | IDC | 6.91e-15 | 5.00e-01 | 0.1569 |
| 55766 | H2AFJ | GSM4909308 | Human | Breast | IDC | 1.10e-47 | 7.46e-01 | 0.158 |
| 55766 | H2AFJ | GSM4909309 | Human | Breast | IDC | 6.44e-14 | 2.98e-01 | 0.0483 |
| 55766 | H2AFJ | GSM4909311 | Human | Breast | IDC | 2.30e-35 | -1.31e-01 | 0.1534 |
| 55766 | H2AFJ | GSM4909312 | Human | Breast | IDC | 3.34e-08 | 8.49e-03 | 0.1552 |
| 55766 | H2AFJ | GSM4909313 | Human | Breast | IDC | 8.83e-09 | 1.68e-01 | 0.0391 |
| 55766 | H2AFJ | GSM4909316 | Human | Breast | IDC | 3.51e-26 | 6.65e-01 | 0.21 |
| 55766 | H2AFJ | GSM4909319 | Human | Breast | IDC | 2.06e-79 | 5.48e-01 | 0.1563 |
| 55766 | H2AFJ | GSM4909320 | Human | Breast | IDC | 9.78e-13 | 2.10e-01 | 0.1575 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa05322 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
| hsa053221 | Cervix | HSIL_HPV | Systemic lupus erythematosus | 19/459 | 137/8465 | 1.40e-04 | 1.74e-03 | 1.40e-03 | 19 |
| hsa04217 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| hsa042171 | Colorectum | SER | Necroptosis | 47/1580 | 159/8465 | 5.21e-04 | 4.44e-03 | 3.22e-03 | 47 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| H2AFJ | insertion | In_Frame_Ins | novel | c.249_250insGTCAGCACAGGAAGCATTCACGTCTGGTCATCA | p.His83_Leu84insValSerThrGlySerIleHisValTrpSerSer | p.H83_L84insVSTGSIHVWSS | Q9BTM1 | protein_coding | TCGA-AN-A03X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| H2AFJ | SNV | Missense_Mutation | novel | c.239N>G | p.Ile80Ser | p.I80S | Q9BTM1 | protein_coding | deleterious_low_confidence(0.02) | possibly_damaging(0.585) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| H2AFJ | SNV | Missense_Mutation | novel | c.29N>C | p.Lys10Thr | p.K10T | Q9BTM1 | protein_coding | deleterious_low_confidence(0.05) | possibly_damaging(0.555) | TCGA-AP-A1E1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| H2AFJ | SNV | Missense_Mutation | rs751251262 | c.181G>A | p.Ala61Thr | p.A61T | Q9BTM1 | protein_coding | deleterious_low_confidence(0.01) | probably_damaging(0.959) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| H2AFJ | SNV | Missense_Mutation | c.357G>T | p.Lys119Asn | p.K119N | Q9BTM1 | protein_coding | deleterious_low_confidence(0.02) | benign(0.027) | TCGA-B5-A0JY-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | doxorubicin | SD | |
| H2AFJ | SNV | Missense_Mutation | c.284N>G | p.Asn95Ser | p.N95S | Q9BTM1 | protein_coding | tolerated_low_confidence(0.15) | benign(0.007) | TCGA-BS-A0UF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| H2AFJ | SNV | Missense_Mutation | c.357N>T | p.Lys119Asn | p.K119N | Q9BTM1 | protein_coding | deleterious_low_confidence(0.02) | benign(0.027) | TCGA-D1-A15X-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| H2AFJ | SNV | Missense_Mutation | novel | c.94C>T | p.His32Tyr | p.H32Y | Q9BTM1 | protein_coding | deleterious_low_confidence(0.04) | benign(0.167) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| H2AFJ | SNV | Missense_Mutation | novel | c.277G>A | p.Glu93Lys | p.E93K | Q9BTM1 | protein_coding | deleterious_low_confidence(0.01) | benign(0.283) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| H2AFJ | SNV | Missense_Mutation | rs371368734 | c.356A>G | p.Lys119Arg | p.K119R | Q9BTM1 | protein_coding | tolerated_low_confidence(0.1) | benign(0.312) | TCGA-2Y-A9H9-01 | Liver | liver hepatocellular carcinoma | Male | >=65 | I/II | Targeted Molecular therapy | sorafenib | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |